Empagliflozin and HFrEF: Known and Possible Benefits of NHE1 Inhibition

Seungho Jun; Miguel A Aon; Nazareno Paolocci

doi:10.1016/j.jacbts.2019.10.005

Empagliflozin and HFrEF: Known and Possible Benefits of NHE1 Inhibition

JACC Basic Transl Sci. 2019 Nov 25;4(7):841-844. doi: 10.1016/j.jacbts.2019.10.005. eCollection 2019 Nov.

Authors

Seungho Jun¹, Miguel A Aon^{2

3}, Nazareno Paolocci^{1

4}

Affiliations

¹ Division of Cardiology, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland.
² Laboratory of Cardiovascular Science, National Institute on Aging, National Institutes of Health, Baltimore, Maryland.
³ Translational Gerontology Branch, National Institute on Aging, National Institutes of Health, Baltimore, Maryland.
⁴ Department of Biomedical Sciences, University of Padova, Padova, Italy.

No abstract available

Keywords: NHE1; SGLT2; cardiac redox balance; diabetes; empagliflozin; heart failure with reduced ejection fraction; mitochondrial energy metabolism.

Publication types

Editorial

Publication types

Grants and funding